GNTLF Stock - Genetic Technologies Limited
Unlock GoAI Insights for GNTLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.67M | $10.35M | $9.22M | $1.33M | $837,865 |
| Gross Profit | $3.90M | $6.01M | $6.47M | $-240,473 | $736,432 |
| Gross Margin | 40.4% | 58.1% | 70.2% | -18.0% | 87.9% |
| Operating Income | $-12,210,212 | $-6,066,319 | $-4,811,005 | $-5,799,309 | $-5,938,503 |
| Net Income | $-12,017,219 | $-11,750,923 | $-7,130,998 | $-7,077,619 | $-6,294,775 |
| Net Margin | -124.2% | -113.6% | -77.4% | -530.3% | -751.3% |
| EPS | $-0.09 | $-0.12 | $-0.08 | $-0.08 | $-0.15 |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Visit WebsiteEarnings History & Surprises
GNTLFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 20, 2025 | — | — | — | — |
Q2 2025 | May 27, 2025 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.03 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.04 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.04 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.04 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.03 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.03 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.05 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.06 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.08 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.09 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.07 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.10 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.14 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.16 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.18 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.18 | — | — |
Latest News
Frequently Asked Questions about GNTLF
What is GNTLF's current stock price?
What is the analyst price target for GNTLF?
What sector is Genetic Technologies Limited in?
What is GNTLF's market cap?
Does GNTLF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GNTLF for comparison